Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that ALRN-6924 effectively protected human hair follicles from cyclophosphamide-induced damage in an ex vivo setting, suggesting it may reduce both acute and permanent chemotherapy-induced alopecia.

In this study of children with nephrotic syndrome treated with cyclophosphamide, 59.4% achieved remission, and 40.6% experienced side effects including nausea, vomiting, and hair loss.

In this animal study, topical pentoxifylline was associated with improved hair regrowth in cyclophosphamide-induced hair loss in male Swiss albino rats.

This study found that the PPARγ modulator NAC-GED-0507-Levo may protect hair follicles from chemotherapy-induced damage, potentially offering a strategy to address irreversible hair loss in cancer patients.

This study concluded that monthly pulse IV cyclophosphamide is effective for severe lupus nephritis in Indian patients, achieving complete or partial remission in 68.9% of cases, though longer follow-up is needed.

This study found that leflunomide combined with prednisone showed good efficacy and tolerance in treating lupus nephritis where cyclophosphamide was ineffective or intolerable.

This study observed that a single intraperitoneal injection of cyclophosphamide caused significant destruction of the intestinal mucosa in albino rats.

This study observed that a combination of low-dose cyclophosphamide and vinorelbine appears safe and has promising antitumor activity in patients with metastatic breast cancer resistant to anthracyclines and taxanes, achieving a 44% objective response rate at 6 months with manageable toxicity levels.

In a study using a mouse model, HF-MSCs were reported to enhance ovarian function in cyclophosphamide-induced premature ovarian failure more effectively than HU-MSCs, potentially by preventing ferroptosis in granulosa cells via the KEAP1/NRF2/HO-1 pathway.

In this case study, intravenous cyclophosphamide pulse therapy effectively improved symptoms of steroid-resistant lupus cystitis and peritonitis, allowing for a reduction in steroid dosage.

This study reports that permanent and severe alopecia is a newly identified complication of the FEC 100–docetaxel regimen used for adjuvant breast cancer treatment.

The study found that for positive-node breast cancer patients aged 50 and older, adding chemotherapy to tamoxifen significantly improved disease-free survival compared to tamoxifen alone.

This guideline outlines the management of systemic lupus erythematosus in adults but reports no new clinical findings.

In a neonatal rat model, this study found that topical CDK2 inhibitors reduced chemotherapy-induced hair loss in 33 to 50% of the animals, suggesting a potential strategy for preventing alopecia in cancer patients.

In this study, different types of catagen in the C57BL/6 mouse model exhibited varying effects on hair follicle melanocytes and melanin distribution, with spontaneous and dexamethasone-induced catagen showing pigment incontinence, while cyclophosphamide-induced catagen retained dendritic melanocytes but increased ectopic melanin.

The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.

This review update suggests that mycophenolate mofetil may increase complete disease remission in proliferative lupus nephritis compared to intravenous cyclophosphamide, but with low certainty of evidence.

This case study reported a 23-year-old woman with chronic myeloid leukemia who developed permanent hair loss after chemotherapy and did not respond to topical minoxidil treatment.

This review describes the variety of mucocutaneous side effects caused by antineoplastic chemotherapy, with emphasis on skin, nails, and mucous membranes, while highlighting potential severity and the possibility of needing to adjust or interrupt treatment in rare cases; it presents no new clinical results.

This study found that azathioprine may improve relapses and disability in patients with neuromyelitis optica spectrum disorder but is associated with higher adverse events compared to mycophenolate mofetil.

This study found that cyclophosphamide induced significant keratinocyte apoptosis in anagen hair follicles of mice, while topical calcitriol-analogs reduced this apoptosis, suggesting a protective effect against chemotherapy-induced alopecia.

This study found that Imuvert consistently protected against alopecia induced by certain chemotherapy drugs in rats, potentially mediated by a monocyte-derived cytokine like interleukin-1.

This study found that enhanced expression of the Sonic hedgehog gene via an adenovirus vector accelerated hair regrowth in mice with chemotherapy-induced alopecia.

In this study, scalp hypothermia with the Theracool™ cooling machine was largely ineffective for preventing alopecia in breast cancer patients undergoing a chemotherapeutic regimen including cyclophosphamide and anthracyclines.

In this study, researchers found that alkylating chemotherapy causes hair follicle stem cells to lose their regenerative ability by initially triggering proliferation followed by apoptosis, leading to permanent regeneration loss.

This study found that certain chemotherapeutic agents, such as cyclophosphamide, disrupt feather formation and induce hair loss in mice by inhibiting cell proliferation through sonic hedgehog gene downregulation.

This article discusses the presentation of chemotherapy-induced anagen effluvium as either diffuse or patterned hair loss and reports no new clinical findings.